Exploring the Role of Genetic Testing in Personalized Oncology Treatment and Patient Prognosis
DOI:
https://doi.org/10.56294/mw2024534Keywords:
Genetic Testing, Personalized Oncology, Targeted Therapy, Cancer Prognosis, Precision MedicineAbstract
Genetic testing is now an important part of specialized cancer care because it gives doctors useful information that can greatly improve treatment results and patients' prognoses. As cancer care moves from one-size-fits-all to more personalized approaches, genetic testing is a key part of finding the exact genes and genetic changes that cause tumors to grow. This lets doctors tailor treatment plans to each person's unique genetic makeup, which increases the chances of success while lowering the risk of side effects. Genetic testing is being used more and more in personalized cancer treatments to help make choices about tailored therapies, immunotherapies, and precision drugs. Oncologists can find the best drugs and treatment plans for each patient by looking at genetic markers and changes that are unique to that patient's cancer. Finding flaws that can be used, like those in the EGFR or BRCA1/2 genes, makes it possible to use tailored treatments that are more exact in how they work and have a higher chance of success than standard chemotherapy. Genetic tests can also help predict how well certain treatments will work, which makes planning treatments smarter and keeps people from having to go through steps that aren't necessary. Genetic testing not only helps doctors choose the best treatment, but it also tells doctors a lot about the patient's outlook. Oncologists can better predict how violent the disease will be, how likely it is that the tumor will spread, and the patient's total chance of life by looking at its genetic makeup. Finding genetic predispositions to cancer return or spread early on lets treatments start on time, which increases the chance of life.
References
Malani, D.; Kumar, A.; Brück, O.; Kontro, M.; Yadav, B.; Hellesøy, M.; Kuusanmäki, H.; Dufva, O.; Kankainen, M.; Eldfors, S.; et al. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 2021, 12, 388–401.
Bohr, A.; Memarzadeh, K. The Rise of Artificial Intelligence in Healthcare Applications. Artif. Intell. Healthc. 2020, 1, 25–60.
Rapport, F.; Clay-Williams, R.; Churruca, K.; Shih, P.; Hogden, A.; Braithwaite, J. The struggle of translating science into action: Foundational concepts of implementation science. J. Eval. Clin. Pract. 2017, 24, 117–126.
Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.; Colquhoun, H.; Kastner, M.; Levac, D.; Ng, C.; Sharpe, J.P.; Wilson, K.; et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med. Res. Methodol. 2016, 16, 15.
Drilon, A.; Siena, S.; Dziadziuszko, R.; Barlesi, F.; Krebs, M.G.; Shaw, A.T.; Braud, F.d.; Rolfo, C.; Ahn, M.J.; Wolf, J.; et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020, 21, 261–270.
Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217.
Crosby, D.; Bhatia, S.; Brindle, K.M.; Coussens, L.M.; Dive, C.; Emberton, M.; Esener, S.; Fitzgerald, R.C.; Gambhir, S.S.; Kuhn, P.; et al. Early Detection of Cancer. Science 2022, 375.
Devilakshmi, S.; Madhumathi, J.; Verma, R.S. Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective. In Resistance to Targeted Anti-Cancer Therapeutics; Springer: Cham, Switzerland, 2015; pp. 33–56.
Esfahani, K.; Roudaia, L.; Buhlaiga, N.; Del Rincon, S.; Papneja, N.; Miller, W. A review of cancer immunotherapy: From the past, to the present, to the future. Curr. Oncol. 2020, 27, S87–S97
Yazbeck, V.; Alesi, E.R.; Myers, J.; Hackney, M.H.; Cuttino, L.W.; Gewirtz, D.A. An overview of chemotoxicity and radiation toxicity in cancer therapy. Adv. Cancer Res. 2022, 155, 1–27.
Published
Issue
Section
License
Copyright (c) 2024 Hiren Hansraj Patadiya, Kunal Meher, Simranjeet Nanda, Rajashree Panigrahi, Uma Bhardwaj, RenukaJyothi.S, Prateek Garg (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
